Daily Bulletin

First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort 2 of the 64Cu/67Cu SARTATE™ neuroblastoma...

Read more: First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

Business News

Why Professional Window Cleaning Is a Must for Melbourne Homes

Let us be honest when was the last time you cleaned your windows properly? Not just a quick wipe, but a proper clean that got into all the corners, sills, and second-storey panes. If you are like mo...

Daily Bulletin - avatar Daily Bulletin

pay.com.au unlocks untapped value through Avios and British Airways partnership

British Airways joins a growing list of transfer partners including Cathay Pacific and Thai Airways, empowering SMEs with expanded redemption options and flexibility  AUSTRALIA, 29 April 2025 — p...

Daily Bulletin - avatar Daily Bulletin

Why Ignoring a Windshield Chip Could Cost You More in the Long Run

(Source) When a stone from the road jumps to your windshield, you hear the distinctive tap. You check the glass window through your reflection to discover one tiny chip that seems insignificant. A sm...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals